Skip to main content
Facebook
Tweet
Welcome
Search form
Search
Menu
Home
About Us
What is ALS?
Mission Statement
Work for EUpALS
Governance
Board of Directors
Patients and Carers Expert Board
Scientific Expert Board
Member Associations
Overview Members
Miquel Valls
APELA
Fundacion Francisco Luzon
MND Iceland
Stichting ALS Nederland
Arsla
Stiftelsen ALS Norsk StØttegruppe
ALS Liga
Aisla Onlus
ALS patiëntenvereniging
The ALS Association of Republic Srpska, Bosnia and Herzegovina
MND Association England, Wales and Northern Ireland
Motus Vita
ALS-tutkimuksen tuki ry
Društvo Distrofikov Slovenije / Muscular Dystrophy Association of Slovenia
EAMDA - European Alliance of Neuromuscular Disorders Association
ALS-MNH Derneği / ALS/MND Association Turkey
Ulla-Carin Lindquist Stiftelse för ALS-forskning
Irish Motor Neurone Disease Association (IMNDA)
Muskelsvindfonden
Research Motor Neurone (RMN)
Foundation LIVE NOW
ALS Association Switzerland
Activities
Membership
Membership request
Partners
Academic Partners
Industry partners
HEREDITARY
Real4reg
News
Newsletters
ALS Trials
ALS Research news
Donate
Contact
You are here
Home
» ALS Research news
ALS Research news
November 28, 2024 - Topline results PTC Therapeutics cardinALS trial
November 12, 2024 - Biogen published results of Phase I study with BIIB078 C9orf72 ASO
October 15, 2024 - uniQure announces dosing first patient in Phase I-II clinical trial of AMT-162 for SOD1-ALS
September 5, 2024 - Decoding regulatory agency decisions - The case of Amylyx's Relyvrio-Albrioza in the US and EU
May 31, 2024 - Biogen Receives European Commission Approval for QALSODY® (tofersen), the First Therapy to Treat a Rare, Genetic Form of ALS
May 17, 2024 - Biogen and Ionis Announce Topline Phase 1-2 Study Results of Investigational Drug in ALS
April 08, 2024 - Amylyx announces formal intention to Remove RELYVRIO®- ALBRIOZA™ from the market, provides update on access to therapy, and on pipeline
March 27, 2024 - Top line results TUDCA
March 25, 2024 - Ferrer and Verge Genomics Announce Agreement to Co-Develop Clinical-Stage ALS Therapy VRG50635
March 11, 2024 - Amylyx announces topline results from global Phase 3 PHOENIX trial of AMX0035 in ALS
February 21, 2024 - Sanofi Himalaya Update for EUpALS
January 26, 2024 - EMA written submission needed
February 26, 2024 - Biogen Community Statement on Tofersen CHMP Opinion
Januari 29, 2024 - European Union funds groundbreaking research into psychedelic therapy
Januari 23, 2024 - Prilenia Announces Clinical Data in Support of its Plans to Initiate Global Phase 3 Study in ALS
Januari 10, 2024 - Ferrer Phase 3 ADORE trial with FAB122 (oral Edaravone) does not meet primary and secondary endpoints
December 11, 2023 - NeuroSense's Phase 2b ALS Trial Achieves Primary Safety and Tolerability & Secondary Clinical Efficacy Endpoints
October 13, 2023 - EMA CHMP negative opinion for AMX-0035 for treatment of ALS in EU upon re-examination
September 28, 2023 - BrainStorm update on FDA review NurOwn for treatment of ALS
September 7, 2023 - ALS EU Coalition
June 23, 2023 - Amylyx Receives EMA CHMP Negative Opinion on its Conditional Marketing Authorisation Application for AMX0035 for ALS in EU
June 22, 2023 - Ferrer extends its clinical study in ALS
May 30, 2023 - Amylyx Pharmaceuticals Provides Update on Ongoing Regulatory Review of AMX0035 for the Treatment of ALS
May 23, 2023 - Wave discontinues FOCUS-C9 trial
April 26, 2023 - Apellis announces discontinuation open-label period MERIDIAN study
April 26, 2023 - FDA Grants Accelerated Approval for QALSODY™ (tofersen) for SOD1-ALS
April 3, 2023 - Cytokinetics discontinues COURAGE-ALS clinical trial of Reldesemtiv
March 3, 2023 - Biogen Provides Update on FDA Advisory Committee Meeting on Tofersen for SOD1-ALS
February 3, 2023 - Amylyx announces completion of enrollment on Phase 3 PHOENIX trial of AMX0035 in ALS
January 10, 2023 - Biogen and Alcyone Therapeutics collaborate on novel device to improve access to neurological ASO therapies
December 5, 2022 - EMA accepts Biogen Tofersen Marketing Authorization Application
October 7, 2022 - TRICALS statement on FDA approval of Amylyx AMX0035
September 29, 2022 - Amylyx Pharmaceuticals Announces FDA Approval of RELYVRIO™ for the Treatment of ALS
September 22, 2022 - With Tofersen, a first effective treatment is becoming available for ALS!
September 16, 2022 - Amylyx Pharmaceuticals announces FDA Advisory Committee Supports Approval of AMX0035 for the Treatment of ALS’
August 30, 2022 - AB Science announces filing of marketing authorization application for Alsitek in the treatment of amyotrophic lateral sclerosis (ALS) and its validation by the European Medicines Agency (EMA))
July 29, 2022 - Biogen ALS Community Statement on FDA acceptance new drug application for Tofersen
July 4, 2022 - Tranquis Therapeutics Announces Successful Completion of Phase 1 Clinical Trial of TQS-168
June 17, 2022 - Cytokinetics Announces Start of Open-Label Extension Study for Patients Completing COURAGE-ALS
June 14, 2022 - Amylyx announces that Health Canada has approved ALBRIOZA™ (also known as AMX0035), with conditions, for the treatment of ALS
June 7, 2022 - Biogen Tofersen new 12-month data show meaningful benefit in people with SOD1-ALS
May 9, 2022 - Amylyx’ AMX0035 further demonstrates safety profile in ALS
April 5, 2022 - Wave announces positive update to ongoing Phase1b-2a FOCUS-C9 study
March 31, 2022 - Biogen ALS Community Statement on discontinuation BIIB078 trial
March 28, 2022 - Biogen and Ionis Announce Topline Phase 1 Study Results of Investigational Drug in C9orf72 Amyotrophic Lateral Sclerosis
March 15, 2022 - TRICALS MAGNET study with lithium carbonate enrolls first participants
March 2, 2022 - UCB Zilucoplan trial arm stopped early in HEALEY ALS Platform
February 5, 2022 - Amylyx Pharmaceuticals Announces EMA Validation of Marketing Authorisation Application (MAA) for AMX0035 for the Treatment of ALS
Janurary 5, 2022 - Amylyx Pharmaceuticals Submits Marketing Authorization Application (MAA) for AMX0035 for the Treatment of ALS
October 17, 2021 - Biogen Announces Topline Results from the Tofersen Phase 3 Study and its Open-Label Extension in SOD1-ALS
September 15, 2021 - Amylyx Pharmaceuticals announces plan to submit NDA for AMX0035 in the treatment of ALS in the coming months
August 20, 2021 - Alexion announces stop of Ultomiris CHAMPION-ALS Phase 3 trial
August 2, 2021 - Cytokinetics Announces Start of COURAGE-ALS, a Phase 3 Clinical Trial of Reldesemtiv in Patients With Amyotrophic Lateral Sclerosis
June 1, 2021 - AB Science announces voluntary hold in clinical studies with masitinib worldwide
May 7, 2021 - Orphazyme announces topline data from pivotal trial of arimoclomol in Amyotrophic Lateral Sclerosis (ALS)
March 5, 2021 - Notice to SOD1 pALS regarding access to Tofersen Compassionate Use - Early Access Program
April 14, 2021 - AMYLYX PHARMACEUTICALS PROVIDES GLOBAL REGULATORY UPDATE ON AMX0035 FOR ALS